“Assessment of skin fibrosis is a crucial prognostic factor in SSc,” says Francesco Del Galdo, from the University of Leeds, UK, “but at present there is no objective validated biomarker to assess this.” The quest for such a biomarker is ongoing and, according to a paper from Del Galdo and colleagues in Annals of the Rheumatic Diseases, might have been achieved in the form of optical coherence tomography (OCT).
